Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies

Surg Oncol Clin N Am. 2004 Oct;13(4):697-709, x. doi: 10.1016/j.soc.2004.06.011.

Abstract

The authors developed a strategy that includes a novel approach of induction full-dose chemotherapy followed by traditional chemoradiation as a neoadjuvant therapy for pancreatic cancer. Here they report the results of a phase I/II trial of gemcitabine, cisplatin, and 5-FU for patients with advanced gastrointestinal malignancies.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Female
  • Fluorouracil / therapeutic use
  • Gastrointestinal Neoplasms / mortality
  • Gastrointestinal Neoplasms / pathology*
  • Gastrointestinal Neoplasms / therapy*
  • Gemcitabine
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Pancreatectomy / methods
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / therapy*
  • Patient Selection
  • Prognosis
  • Radiotherapy Dosage
  • Radiotherapy, Adjuvant
  • Remission Induction
  • Survival Analysis
  • Treatment Outcome

Substances

  • Deoxycytidine
  • Cisplatin
  • Fluorouracil
  • Gemcitabine